Cancer. Adverse effects of antitumor therapy

Posted by Francisco Molina Rueda

Professor Raquel Abalo participates in various publications on the consequences of chemotherapy for cancer treatment


Raquel Abalo, Professor of Pharmacology at the URJC (Department of Basic Health Sciences), participates in the preparation of two special issues in the journal Frontiers in Pharmacology and in the publication of a book for the publisher Nova Medicine and Health.

The first special, which you can consult here, deals with the adverse effects of chemotherapy in cancer treatment. This issue discusses the consequences of antitumor treatment, as well as strategies to improve tolerance and reduce sequelae. The second special titled, "Cancer Therapy: The Challenge of Handling a Double-Edged Sword", aims to establish a forum for original research (preclinical, clinical, translational) and to collect review articles focused on side effects associated with systemic cancer treatment (including conventional chemotherapy, targeted therapy, hormonal therapy and immunotherapy) and its management. 

Finally, Dr. Abalo has published, together with Kulmira Nurgali (Victoria University, Australia) the book entitled "Platinum-Based Chemotherapy: Clinical Uses, Efficacy and Side Effects", from Nova Publisher. Platinum-based chemotherapy is one of the first chemotherapies introduced into clinics and remains the first-line treatment, used alone or in combination with other antineoplastic therapy and/or radiation, for many types of cancer in both adults and children. This work offers the reader an overview of this therapy, as well as an update on some of the most relevant specific issues of said treatment.




Last modified on Thursday, October 27, 2022 at 17:00